On Tuesday, Rani Therapeutics Holdings Inc (NASDAQ: RANI) opened lower -4.70% from the last session, before settling in for the closing price of $1.49. Price fluctuations for RANI have ranged from $0.39 to $3.87 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 4.78% over the past five years. Company’s average yearly earnings per share was noted 59.52% at the time writing. With a float of $79.32 million, this company’s outstanding shares have now reached $97.55 million.
Rani Therapeutics Holdings Inc (RANI) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Rani Therapeutics Holdings Inc is 18.69%, while institutional ownership is 12.13%. The most recent insider transaction that took place on Oct 23 ’25, was worth 1,260,417. In this transaction Director of this company bought 2,083,334 shares at a rate of $0.60, taking the stock ownership to the 2,083,334 shares. Before that another transaction happened on Oct 21 ’25, when Company’s 10% Owner sold 4,000,000 for $2.77, making the entire transaction worth $11,074,000. This insider now owns 2,379,194 shares in total.
Rani Therapeutics Holdings Inc (RANI) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.16 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.23) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 35.44% during the next five years compared to 4.78% growth over the previous five years of trading.
Rani Therapeutics Holdings Inc (NASDAQ: RANI) Trading Performance Indicators
Check out the current performance indicators for Rani Therapeutics Holdings Inc (RANI). In the past quarter, the stock posted a quick ratio of 0.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 143.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.27 in one year’s time.
